Discussion stirs around Spark Therapeutics, Inc. (NASDAQ:ONCE) this week; here is what analysts are saying.

September 16, 2018 - By Bradley Stiles

Spark Therapeutics, Inc. (NASDAQ:ONCE) LogoInvestors sentiment is 1.19 in 2018 Q2. Its the same as in 2018Q1. It has no change, as 17 investors sold Spark Therapeutics, Inc. shares while 46 reduced holdings. only 24 funds opened positions while 51 raised stakes. 37.08 million shares or 0.93% more from 36.74 million shares in 2018Q1 were reported.
Tower Rech Ltd Com (Trc) reported 11 shares. Wellington Mngmt Grp Inc Llp invested in 0.07% or 3.54M shares. Moreover, Art Limited Co has 0.14% invested in Spark Therapeutics, Inc. (NASDAQ:ONCE). Bokf Na holds 0.04% or 15,911 shares in its portfolio. Financial Architects accumulated 170 shares. Bnp Paribas Arbitrage stated it has 0% in Spark Therapeutics, Inc. (NASDAQ:ONCE). Comml Bank Of Montreal Can owns 284 shares or 0% of their US portfolio. Winslow Evans & Crocker has 0% invested in Spark Therapeutics, Inc. (NASDAQ:ONCE). Clearbridge Invests Limited Liability stated it has 0.04% of its portfolio in Spark Therapeutics, Inc. (NASDAQ:ONCE). Pdts Partners Limited Liability Com has invested 0.63% in Spark Therapeutics, Inc. (NASDAQ:ONCE). Ubs Asset Management Americas Inc stated it has 0% of its portfolio in Spark Therapeutics, Inc. (NASDAQ:ONCE). Bailard stated it has 37,000 shares or 0.18% of all its holdings. Fmr Llc holds 0.05% in Spark Therapeutics, Inc. (NASDAQ:ONCE) or 5.54M shares. Alps holds 0.01% or 40,496 shares in its portfolio. Axa, France-based fund reported 62,915 shares.

Spark Therapeutics, Inc. (NASDAQ:ONCE) Ratings Coverage

Among 14 analysts covering Spark Therapeutics (NASDAQ:ONCE), 5 have Buy rating, 1 Sell and 8 Hold. Therefore 36% are positive. Spark Therapeutics had 21 analyst reports since March 29, 2018 according to SRatingsIntel. The firm earned “Outperform” rating on Monday, June 25 by BMO Capital Markets. The firm has “Buy” rating given on Thursday, March 29 by Mizuho. Stifel Nicolaus maintained Spark Therapeutics, Inc. (NASDAQ:ONCE) on Wednesday, May 9 with “Buy” rating. The stock of Spark Therapeutics, Inc. (NASDAQ:ONCE) has “Neutral” rating given on Wednesday, August 8 by UBS. The rating was downgraded by Credit Suisse on Tuesday, August 7 to “Underperform”. The stock of Spark Therapeutics, Inc. (NASDAQ:ONCE) earned “Buy” rating by Cantor Fitzgerald on Tuesday, May 8. RBC Capital Markets downgraded the stock to “Sector Perform” rating in Thursday, July 19 report. As per Tuesday, May 22, the company rating was maintained by Cantor Fitzgerald. As per Tuesday, May 1, the company rating was maintained by JP Morgan. The stock of Spark Therapeutics, Inc. (NASDAQ:ONCE) has “Outperform” rating given on Monday, July 9 by Credit Suisse. Below is a list of Spark Therapeutics, Inc. (NASDAQ:ONCE) latest ratings and price target changes.

08/08/2018 Broker: UBS Old Rating: Neutral New Rating: Neutral Old Target: $80 New Target: $53 Maintain
08/08/2018 Broker: Barclays Capital Old Rating: Overweight New Rating: Overweight Old Target: $85 New Target: $77 Maintain
08/08/2018 Broker: BMO Capital Markets Old Rating: Outperform New Rating: Market Perform Old Target: $98 Downgrade
08/08/2018 Broker: Stifel Nicolaus Old Rating: Buy New Rating: Buy Old Target: $76 New Target: $68 Maintain
07/08/2018 Broker: Credit Suisse Old Rating: Outperform New Rating: Underperform Old Target: $98 Downgrade
19/07/2018 Broker: RBC Capital Markets Old Rating: Outperform New Rating: Sector Perform Old Target: $100 Downgrade
09/07/2018 Broker: Credit Suisse Old Rating: Outperform New Rating: Outperform Old Target: $75 New Target: $98 Maintain
28/06/2018 Broker: FBR Capital Rating: Neutral New Target: $74 Initiates Coverage On
25/06/2018 Broker: BMO Capital Markets Old Rating: Outperform New Rating: Outperform Old Target: $78 New Target: $98 Maintain
22/05/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $103.0000 Maintain

The stock decreased 0.15% or $0.09 during the last trading session, reaching $58.95. About 440,462 shares traded. Spark Therapeutics, Inc. (NASDAQ:ONCE) has declined 28.27% since September 16, 2017 and is downtrending. It has underperformed by 43.89% the S&P500.

Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. The company has market cap of $2.22 billion. The Company’s products include voretigene neparvovec, which is in Phase III clinical trial for the treatment of genetic blinding conditions called inherited retinal diseases caused by non sex-linked, autosomal recessive, or biallelic mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia. It currently has negative earnings. The companyÂ’s products also comprise SPK-7001 that is in Phase 1/2 trial for choroideremia; SPK-9001, which is in Phase 1/2 trial for hemophilia B; and SPK-8011 that is in Phase 1/2 trial hemophilia A.

More recent Spark Therapeutics, Inc. (NASDAQ:ONCE) news were published by: Globenewswire.com which released: “Report: Exploring Fundamental Drivers Behind Fiesta Restaurant Group, Emerge Energy Services LP, Collegium …” on August 24, 2018. Also Nasdaq.com published the news titled: “Is Spark Therapeutics a Bad News Buy?” on August 18, 2018. Seekingalpha.com‘s news article titled: “Sangamo (Part V): Assessing The Prospects Of SB-913” with publication date: September 11, 2018 was also an interesting one.

Spark Therapeutics, Inc. (NASDAQ:ONCE) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: